Samsung Electronics America to Cut 739 New Jersey Jobs as Texas Headquarters Move Advances 
Netflix Stock Drops After Weak Q3 Outlook Overshadows Mixed Q2 Earnings 
Ryanair Warns Summer Airfares May Stay Lower as Quarterly Profit Misses Estimates 
Chalco Shares Jump as Chinalco Plans Up to $300 Million Stake Increase 
Sam Altman Admits OpenAI Missteps, Promises Major AI Comeback Focused on User Freedom 
ASML Trillion-Dollar Valuation: Can Europe’s AI Chip Giant Reach the Historic Milestone? 
Trump Criticizes ABC, NBC and CNN for Limiting Coverage of Election Speech 
DeepSeek Eyes $74 Billion Valuation Ahead of Planned China IPO 
South Korea’s Coupang Fine Sparks U.S. Criticism, Raising Concerns Over Bilateral Ties 
SpaceX Aborts Starship Test Flight as Engine Issue Delays Launch 
Tesla Stock Outlook: Strong EV Sales Boost Earnings, but AI Projects Drive Long-Term Value 
Why Maruti Suzuki Is Losing Market Share in India as SUVs and Premium Features Gain Popularity 
Nationwide Data Center Protests Highlight Growing Backlash Against AI Expansion 
SpaceX Targets Thursday Launch for Starship's 13th Test Flight After Last-Minute Delay 
TSMC Sees Multi-Year AI Chip Demand as Arizona Expansion Reaches $265 Billion 
Samsung Biologics has announced plans to acquire Swiss contract drug manufacturer PolyPeptide in an all-cash deal valued at approximately 1.46 billion Swiss francs ($1.81 billion), strengthening its position in the fast-growing peptide therapeutics market.
Under the proposed transaction, Samsung Biologics will offer 44.31 Swiss francs per share, representing a 6.1% premium to PolyPeptide’s closing price of 41.75 Swiss francs on Friday. The South Korean biotech company expects to launch the tender offer by the end of August, with the acquisition targeted for completion before the end of the year.
The acquisition is part of Samsung Biologics’ strategy to expand its contract development and manufacturing capabilities, particularly in peptide-based medicines. The company sees strong growth opportunities in therapies for obesity and diabetes, including GLP-1 drugs, a segment experiencing surging global demand.
PolyPeptide’s board of directors has unanimously recommended that shareholders accept the offer, signaling strong support for the transaction.
Samsung Biologics also said it intends to acquire all remaining shares after the tender offer through a squeeze-out process, allowing it to delist PolyPeptide from the SIX Swiss Exchange and operate the company as a wholly owned subsidiary.
The deal already has the backing of Draupnir Holding, PolyPeptide’s largest shareholder, which controls approximately 55.65% of the company. Draupnir confirmed it will tender all of its shares into Samsung Biologics’ offer.
Earlier this year, PolyPeptide disclosed that Draupnir was reviewing strategic options for its majority stake. Draupnir’s parent organization, the Cryosphere Foundation, has previously been linked to Swedish billionaire Frederik Paulsen.
If completed, the acquisition would significantly enhance Samsung Biologics’ manufacturing portfolio and strengthen its presence in the rapidly expanding global market for peptide-based pharmaceutical ingredients. The move also reflects growing competition among contract drug manufacturers seeking to capitalize on increasing demand for innovative biologic and metabolic disease treatments.
